Company Overview

Caris Life Sciences, Inc. (Caris) is a leading, patient-centric, next-generation AI TechBio company and a pioneer in precision medicine. Founded in 2008 and headquartered in Irving, Texas, Caris is actively developing and commercializing innovative solutions to transform healthcare. The company operates at the intersection of molecular science and artificial intelligence, focusing on the oncology market. It provides comprehensive genomic profiling and precision medicine solutions by leveraging advanced AI and machine learning algorithms. This approach has enabled Caris to build a large-scale, multimodal clinico-genomic database, essential for analyzing and understanding the molecular complexity of diseases. The convergence of next-generation sequencing, AI, machine learning, and high-performance computing forms a differentiated platform for developing advanced precision medicine diagnostics for early detection, diagnosis, monitoring, therapy selection, and drug development.

Business Segments & Services

Caris operates through two primary business segments:

Molecular Profiling Services

This segment includes MI Profile, a tissue-based molecular profiling solution, and Caris Assure, a blood-based molecular profiling solution designed for cancer treatment. These services analyze DNA, RNA, and protein markers to provide comprehensive genomic profiling of tumors, thereby enabling personalized treatment decisions for patients.

Pharma Research and Development Services

This segment offers laboratory delivery, strategic data, and research services to biopharmaceutical customers. Caris partners with pharmaceutical companies to accelerate biomarker discovery and advance drug development programs.

Market Capitalization & Key Metrics

Caris Life Sciences, Inc. currently has a market capitalization of $9.58 Billion, establishing it as a significant player within the precision medicine space.

IPO Details

Caris Life Sciences announced the pricing of its initial public offering (IPO) in June 2025. The offering comprised 23,529,412 shares of common stock at a public offering price of $21.00 per share, marking its official transition to a public company.

Financial Performance

Q2 2025 Results

Caris reported strong financial performance for the second quarter of 2025:

- Revenue: Total revenue reached $181.4 million, an increase of 81.3% over the corresponding prior year period.

- Clinical Volume: Completed 50,032 clinical therapy selection cases, a 22.0% increase over the corresponding prior year period.

- Gross Margin: Achieved a gross margin of 62.7%, representing a 2,514 basis points improvement over the corresponding prior year period.

- Adjusted EBITDA: Reported positive Adjusted EBITDA of $16.7 million.

- Cash Flow: Generated positive net cash flow from operating activities of $7.3 million and positive free cash flow of $5.9 million.

Annual Performance (2024)

In the year 2024, Caris Life Sciences reported annual revenue of $412.26 million, demonstrating 34.67% growth. This brought the company's revenue for the last twelve months to $533.85 million.

2025 Outlook

Caris Life Sciences anticipates its full-year 2025 revenue to fall within the range of $675.0 million to $685.0 million. This projection represents a growth rate of 64% to 66% compared to full-year 2024. Clinical therapy selection volume is expected to grow between 19% and 21% compared to full-year 2024.

Competitive Advantages & Database

Caris continues to expand its clinico-genomic database, now one of the world's largest and most comprehensive. It includes over 529,000 Whole Exomes, 580,000 Whole Transcriptomes, and 600,000 profiles with matched molecular data and clinical outcomes. The company's Precision Oncology Alliance (POA) has grown to 97 sites, and Caris publications have surpassed 1,100, underscoring its scientific leadership in the field.

Key Product Developments

Pricing Improvements

The average selling price (ASP) for MI Profile increased by 53.1% year-over-year, reaching $3,379. This growth was significantly influenced by the recent FDA approval of MI Cancer Seek, which led to an increase in Medicare FFS pricing from $3,500 to $8,455.

Caris Assure Platform

Studies demonstrated remarkable performance metrics for the Caris Assure platform, including:

- 96.8% positive predictive value for therapy selection.

- 33.4 hazard ratio for minimal residual disease detection.

- 83.1-95.7% sensitivity for multi-cancer early detection at 99.6% specificity.

Global Presence

Headquartered in Irving, Texas, Caris Life Sciences operates globally with offices in Phoenix, New York, Cambridge (MA), Tokyo (Japan), and Basel (Switzerland), enabling it to serve patients and partners across multiple international markets.

Stock Performance

CAI reached its all-time high on August 22, 2025, with a price of $42.50 USD. Its all-time low was $25.40 USD, recorded on July 7, 2025. Over the past year, Caris Life Sciences, Inc. has shown a 22.67% increase in stock value.

The company represents a rapidly growing player in the precision medicine and AI-driven healthcare diagnostics sector. Its strong revenue growth, expanding margins, and comprehensive approach to molecular profiling position it well for continued market expansion and future success.